ALCL

September 11, 2017September 11, 2017

Advisory Agency Decision Will Make Lymphoma Therapy Adcetris More Accessible in UK

News

Britain’s national health service advisory agency has made a decision that will make Adcetris (brentuximab vedotin) more accessible as a treatment for an aggressive type of lymphoma. The National Institute for Health and ... Read more

April 8, 2016April 8, 2016

Patient-reported Outcomes in Lymphoma Clinical Trials Are Recognized as Important Tools

News

Patient-reported outcomes in clinical trials of brentuximab vedotin for Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) show improvements in patients’ health-related quality of life, emphasizing their importance for patient management ... Read more

January 20, 2016January 20, 2016

ALC Lymphoma’s Origin Traced to the Thymus, Raising Treatment Possibilities

News

Researchers in the U.K. have traced the origins of anaplastic large cell lymphoma (ALCL) to the thymus, raising the possibility that new treatments may be designed to more effectively prevent ALCL relapse. Their study was published in Nature Communications. ALCL is ... Read more

January 14, 2016January 14, 2016

Origins of Aggressive Childhood Lymphona Found, Offering Hope for New Treatments

News

Researchers at the University of Cambridge in the U.K. say they have traced the origins of anaplastic large cell lymphoma (ALCL), finding that the malignancy originates in early cells of the thymus, ... Read more